An immigrant from India, Veenu Aishwarya is an innovator and a result-oriented biotechnology entrepreneur. He received his biomedical research training while working as a visiting scholar at the Perelman School of Medicine, University of Pennsylvania in Philadelphia. At AUM LifeTech, Mr. Aishwarya has been leading, developing, and strategizing applications of AUM LifeTech’s proprietary next-generation RNA Silencing FANA Antisense Oligonucleotide Technology (FANA ASO) for personalized medicine. Mr. Aishwarya has over 15 years of experience in discovery, optimization, and development of nucleic acids therapeutics. Mr. Aishwarya has invented several new medical applications of FANA ASO technology including the use of FANAs for cancer immunotherapy. Mr. Aishwarya has filed several patents on the use of FANA ASO technology for multiple research and therapeutic applications. Several of his inventions and products have shown significant commercial value in biomedical research and therapeutic development. Most recently, under Mr. Aishwarya’s leadership, AUM LifeTech was selected by the NIH as a part of the BIO Innovation Zone 2021. The Innovation Zone showcases NIH-funded small businesses and their cutting- edge healthcare technologies. In 2017, Mr. Aishwarya was recognized as Millennials to Watch in Life Sciences by the Philadelphia Business Journal. In 2018, he was recognized as one of the 2018 Health Care Innovators by the Philadelphia Business Journal. In 2019, Mr. Aishwarya was recognized as the Forty under 40 business leaders by the Philadelphia Business Journal. He is also an invited member of the Philadelphia Leadership Trust and recognized as a Business Influencer by the Philadelphia Business Journal in 2020. Most recently, Mr. Aishwarya was recognized as the 2021 Diversity Leaders in Business by the Philadelphia Business Journal. Mr. Aishwarya serves on the editorial board of Molecular Therapy – Nucleic Acids (Nature Publishing Group). He is a nominated member of the RNAi Therapeutics Committee of the American Society of Gene and Cell Therapy and the Scientific Advisory Council of the Oligonucleotide Therapeutics Society. He is also a member of The American Association of Cancer Research, The American Society of Gene and Cell Therapy, The American Association for the Advancement of Science, The New York Academy of Sciences, and The International Society of Nucleosides, Nucleotides and Nucleic Acids. He was also selected for a young scientist award program by the Keystone Symposia. He has authored several research articles and invited book chapters in publications like BMC, Oxford, Elsevier and Springer. He serves a referee/reviewer at journals like – Journal of Molecular Biology (Elsevier), Oncogene (Nature Publishing Group), BMC Genomics, Molecular Therapy – Nucleic Acids (Nature Publishing Group) and Journal of Biomedical Research. Mr. Aishwarya has been invited, on several occasions, to write on leadership and entrepreneurship by Fortune Magazine. Mr. Aishwarya has also been a Milken Institute Assocaite. The Milken Institute is an independent economic think tank whose mission is to improve the lives and economic conditions of diverse populations in the United States and around the world by helping business and public policy leaders identify and implement innovative ideas for creating broad-based prosperity. The Milken Institute Associates provides a vital link between the worlds of business, government, economics and philanthropy. Mr. Aishwarya has been a frequently invited delegate at highly regarded global interdisciplinary forums like Forbes Health Care Summit, Fortune Brainstorm TECH, JP Morgan Healthcare conference, Milken Institute Global Conference, Partnering for Cures (Faster cures) and TEDMED.